No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

A retrospective study explored the impact of preexisting cardiovascular disease on adverse events in patients with hematologic malignancies receiving BTK inhibitors.

HealthDay News — Conditions offering alternative explanations for lung cancer symptoms are associated with increased diagnostic intervals, according to a study published online Aug. 23 in the British ...

Study compared telehealth with in-person meeting as a modality for effective delivery of early palliative care.

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

Scott E. Hadland, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues recommend that acute pain should be treated using a multimodal approach, including appropriate use of ...

Researchers sought to determine whether complete remission with partial hematological recovery is beneficial in patients with AML.

HealthDay News — The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study published online ...

The incidence of head and neck cancer increased among patients in the cannabis-related disorder group compared with patients without cannabis-related disorder (0.285% vs 0.091%, respectively).

In a retrospective study, investigators compared the risk of progression to end-stage kidney disease (ESKD) following partial nephrectomy and radical nephrectomy among patients with preoperative stage ...

Inotuzumab ozogamicin (InO) is an active antibody-drug conjugate that works by delivering the chemotherapeutic payload calicheamicin to cells expressing CD22. Studies demonstrate that InO elicits high ...